SCHEMBL16645204

SCHEMBL16645204

O=C(COc1cccnc1)N1CCc2cc(CN3CCN(C(=O)C4CCOCC4)CC3)ccc2C1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.52
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 4/20 0.44
ROCK2 O75116 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.41
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
MAPT P10636 2/20 0.41
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
CPT2 P23786 2/20 0.40
CPT1A P50416 2/20 0.40
CYP2C19 P33261 1/20 0.39
USP2 O75604 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17999906 0.91 NAMPT (0.51) NAMPTKDM4EALDH1A1ROCK2PTGDR2
SCHEMBL17969240 0.89 NAMPT (0.53) NAMPTKDM4EALDH1A1ROCK2PTGDR2
SCHEMBL17969249 0.84 NAMPT (0.52) NAMPTKDM4EALDH1A1PTGDR2TDP1
SCHEMBL16645179 0.82 NAMPT (0.62) NAMPTMAPTCPT2CPT1A
SCHEMBL17969253 0.82 NAMPT (0.64) NAMPTKDM4EALDH1A1PTGDR2LMNA
SCHEMBL16634812 0.80 CYP2C19 (0.48) KDM4EALDH1A1LMNATDP1CYP2C19
SCHEMBL16645229 0.78 NAMPT (0.67) NAMPTKDM4EALDH1A1ROCK2PTGDR2
SCHEMBL16634827 0.76 ESR2 (0.52) KDM4EALDH1A1LMNATDP1PRMT5
SCHEMBL16634888 0.75 NAMPT (0.62) NAMPTKDM4EALDH1A1PTGDR2LMNA
SCHEMBL4516661 0.74 HDAC6 (0.56) KDM4EALDH1A1LMNATDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT NAMPT 1/4885KDM4E 760/4885ALDH1A1 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.